SFTPD Human, Sf9
Sf9, Baculovirus cells.
Surfactant Protein D, Lung Surfactant Protein D, Collectin-7, COLEC7, SFTP4, PSP-D, SP-D, Surfactant-Associated Protein, Pulmonary 4, Surfactant, Pulmonary-Associated Protein D, Pulmonary Surfactant-Associated Protein D, Pulmonary Surfactant Apoprotein, PSPD.
Greater than 90.0% as determined by SDS-PAGE.
Description
SFTPD produced in Sf9 Baculovirus cells is a single, glycosylated polypeptide chain containing 363 amino acids (22-375 a.a.) and having a molecular mass of 36.5kDa. (Molecular size on SDS-PAGE will appear at approximately 40-57kDa).
SFTPD is expressed with a 9 amino acid His tag at C-Terminus and purified by proprietary chromatographic techniques.
Product Specs
Surfactant pulmonary-associated protein D (SFTPD) is a C-type lectin found in the collectin family. It is produced in various tissues, notably the lung's respiratory epithelial cells. SFTPD consists of a C-type lectin domain and a collagen-like domain. Classified as a humoral molecule within the innate immune system, SFTPD is believed to play a role in chronic periodontitis. Additionally, it is involved in the progression of both acute and chronic lung inflammation. Reduced levels of bronchoalveolar SFTPD are a characteristic of several human lung diseases. SFTPD contributes to the lungs' defense mechanisms by protecting against inhaled microorganisms, organic antigens, and toxins. It interacts with complexes such as bacterial lipopolysaccharides, oligosaccharides, and fatty acids, and it regulates leukocyte activity in immune responses. SFTPD also participates in the extracellular reorganization and turnover of pulmonary surfactant. It exhibits strong binding affinity for maltose residues and, to a lesser extent, other alpha-glucosyl moieties.
Produced in Sf9 Baculovirus cells, SFTPD is a single, glycosylated polypeptide chain. It comprises 363 amino acids (with amino acids 22-375 being of particular significance) and has a molecular mass of 36.5 kDa. On SDS-PAGE, the molecular size appears to be approximately 40-57 kDa. This SFTPD protein is engineered with a 9 amino acid His tag at the C-terminus and is purified using proprietary chromatographic techniques.
The product is a sterile, filtered solution that is colorless.
The SFTPD protein solution is provided at a concentration of 0.25 mg/ml. The solution is formulated with 10% glycerol and Phosphate Buffered Saline (pH 7.4).
For optimal storage, keep the product at 4°C if the entire vial will be used within 2-4 weeks. For long-term storage, it is recommended to freeze the product at -20°C. To further enhance stability during long-term storage, consider adding a carrier protein such as HSA or BSA (0.1%). Minimize the number of freeze-thaw cycles to maintain product integrity.
The purity of SFTPD is determined by SDS-PAGE analysis and is consistently greater than 90.0%.
Surfactant Protein D, Lung Surfactant Protein D, Collectin-7, COLEC7, SFTP4, PSP-D, SP-D, Surfactant-Associated Protein, Pulmonary 4, Surfactant, Pulmonary-Associated Protein D, Pulmonary Surfactant-Associated Protein D, Pulmonary Surfactant Apoprotein, PSPD.
Sf9, Baculovirus cells.
ADPEMKTYSH RTMPSACTLV MCSSVESGLP GRDGRDGREG PRGEKGDPGL PGAAGQAGMP GQAGPVGPKG DNGSVGEPGP KGDTGPSGPP GPPGVPGPAG REGPLGKQGN IGPQGKPGPK GEAGPKGEVG APGMQGSAGA RGLAGPKGER GVPGERGVPG NTGAAGSAGA GPQGSPGAR
GPPGLKGDKG IPGDKGAKGE SGLPDVASLR QQVEALQGQV QHLQAAFSQY KKVELFPNGQ SVGEKIFKTA GFVKPFTEAQ LLCTQAGGQL ASPRSAAENA ALQQLVVAKN EAAFLSMTDS KTEGKFTYPT GESLVYSNWA PGEPNDDGGS EDCVEIFTNG KWNDRACGEK RLVVCEFHHH HHH.
Product Science Overview
Surfactant Protein D (SP-D) is a crucial component of the pulmonary surfactant system, which plays a vital role in maintaining lung function and immune defense. SP-D is a member of the collectin family of proteins, which are characterized by their ability to bind to carbohydrate structures on the surface of pathogens, facilitating their clearance from the lungs.
SP-D is synthesized by alveolar type II cells in the lungs and is composed of a collagen-like domain and a carbohydrate recognition domain. This structure allows SP-D to bind to a variety of pathogens, including bacteria, viruses, and fungi, and to modulate the immune response by interacting with immune cells . SP-D has been shown to have anti-inflammatory properties, reducing the release of pro-inflammatory mediators and decreasing the recruitment of inflammatory cells to the lungs .
Recombinant human SP-D (rhSP-D) has been successfully produced to mimic the structure and function of native SP-D. This recombinant form is produced using the Sf9 insect cell expression system, which allows for the production of large quantities of the protein with high purity and activity . The use of rhSP-D has been explored in various preclinical and clinical studies to evaluate its potential therapeutic applications.
One of the primary areas of interest for rhSP-D is its potential use in the treatment of bronchopulmonary dysplasia (BPD), a chronic lung disease that affects preterm infants. BPD is characterized by lung inflammation and injury, which can lead to long-term respiratory problems . Studies have shown that treatment with rhSP-D can reduce lung inflammation and improve lung function in animal models of BPD . Additionally, rhSP-D has been investigated for its potential to prevent and treat other respiratory conditions, such as acute respiratory distress syndrome (ARDS) and chronic obstructive pulmonary disease (COPD) .
The safety and efficacy of rhSP-D are currently being evaluated in clinical trials. For example, a phase I safety trial is being conducted to assess the safety profile of a recombinant fragment of human SP-D (rfhSP-D) in preterm infants with respiratory distress syndrome . This trial aims to determine the optimal dose of rfhSP-D and to evaluate its potential to reduce the incidence and severity of BPD .
